Impact of First Line Antiangiogenic Therapy Duration on Nivolumab Outcome in Metastatic Renal Cell Carcinoma Patients Treated in the GETUG—AFU 26 NIVOREN

Powles, 2021, ESMO clinical practice guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma, Ann Oncol, 32, 1511, 10.1016/j.annonc.2021.09.014 Choueiri, 2020, Targeting the HIF2–VEGF axis in renal cell carcinoma, Nat Med, 26, 1519, 10.1038/s41591-020-1093-z Flippot, 2018, Immune checkpoint inhibitors: toward new paradigms in renal cell carcinoma, Drugs, 78, 1443, 10.1007/s40265-018-0970-y Motzer, 2015, Nivolumab versus everolimus in advanced renal-cell carcinoma, N Engl J Med, 373, 1803, 10.1056/NEJMoa1510665 Rini, 2019, Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma, N Engl J Med, 380, 1116, 10.1056/NEJMoa1816714 Motzer, 2021, Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma, N Engl J Med, 384, 1289, 10.1056/NEJMoa2035716 Choueiri, 2021, Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma, N Engl J Med, 384, 829, 10.1056/NEJMoa2026982 Motzer, 2018, Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma, N Engl J Med, 378, 1277, 10.1056/NEJMoa1712126 Stewart, 2015, Sunitinib treatment exacerbates intratumoral heterogeneity in metastatic renal cancer, Clin Cancer Res, 21, 4212, 10.1158/1078-0432.CCR-15-0207 Guislain, 2015, Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma, Cancer Immunol Immunother, 64, 1241, 10.1007/s00262-015-1735-z Escudier, 2017, CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma, Eur Urol, 72, 962, 10.1016/j.eururo.2017.02.010 Wells, 2020, Clinical outcomes of first-line sunitinib followed by immuno-oncology checkpoint inhibitors in patients with metastatic renal cell carcinoma, Clin Genitourin Cancer, 18, e350, 10.1016/j.clgc.2019.12.007 Jeyakumar, 2017, Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy, J Immunother Cancer, 5, 82, 10.1186/s40425-017-0287-5 Carril Ajuria, 2021, 687P NIVOREN GETUG-AFU 26 translational study: baseline peripheral cytokines predict survival in metastatic clear cell renal carcinoma (RCC) treated with nivolumab, Ann Oncol, 32, S704, 10.1016/j.annonc.2021.08.083 Carril-Ajuria, 2022, Baseline circulating soluble factors as predictors of response to nivolumab in metastatic clear cell renal cell carcinoma (mRCC): a validation study within the NIVOREN GETUG-AFU 26 translational study, J Clin Oncol, 40, 4552, 10.1200/JCO.2022.40.16_suppl.4552 Albiges, 2021, Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: results from the CABOREAL Early Access Program, Eur J Cancer, 142, 102, 10.1016/j.ejca.2020.09.030 Elaidi, 2015, Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma, Ann Oncol, 26, 378, 10.1093/annonc/mdu552 Al-Marrawi, 2013, The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients, Target Oncol, 8, 203, 10.1007/s11523-012-0252-7 Motzer, 2013, Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial, Lancet Oncol, 14, 552, 10.1016/S1470-2045(13)70093-7 Ko, 2015, The international metastatic renal cell carcinoma database consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study, Lancet Oncol, 16, 293, 10.1016/S1470-2045(14)71222-7